%0 Journal Article
%T Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy
%A Bian Li
%A Jiang Ze-fei
%A Jin Fu-quan
%A Li Fan
%A Qu Ze-rui
%A Wang Tao
%A Zhang Shao-hua
%J Archive of "Cancer Biology & Therapy".
%D 2018
%R 10.1080/15384047.2017.1414761
%X In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab, lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients. Two patients with metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy were treated with pembrolizumab (2 mg/Kg, day1) plus albumin-bound paclitaxel (125 mg/m2, day1,8) every 3 weeks. CT evaluation and HER2 ECD test were performed every 2 cycles. Both of the two patients achieved remarkable response with Partial Remission (PR), meanwhile serum HER2 ECD levels (the upper normal limit is 15 ng/ml) showed a remarkable decreases(compared to the base line decreases 75% and 60% respectively). The results indicate that regimen of pembrolizumab combination with albumin-bound paclitaxel might produce response in patients with HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy
%K Albumin-bound paclitaxel
%K Pembrolizumab
%K metastatic breast cancer
%K multi-anti-HER2 targeted therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902233/